Shapiro W R
Arch Neurol. 1975 Oct;32(10):653-6. doi: 10.1001/archneur.1975.00490520023002.
A new antodepressant drug, clomipramine hydrochloride, closely related to imipramine hydrochloride, was used to treat four patients suffering from cataplexy, sleep paralysis, and hypnagogic hallucinations. Attacks of cataplexy were associated with rapid-eye-movement (REM) electroencephalographic patterns. Cloripramine, in doses of 25 to 75 mg/day, completely stopped all attacks of cataplexy, sleep paralysis, and hypnagogic hallucinations within 48 hours of initial therapy. The patients have been free of symptoms for periods of 10 to 21 months. Side effects included impotence in the male patients, but no hematologic, cardiovascular, hepatic, or renal toxic effects were observed. Available evidence suggests that such drugs inhibit those brain stem systems that control the toxic components of REM sleep.
一种新型抗抑郁药物盐酸氯米帕明，与盐酸丙咪嗪密切相关，被用于治疗四名患有猝倒症、睡眠瘫痪症和入睡幻觉症的患者。猝倒症发作与快速眼动（REM）脑电图模式有关。盐酸氯米帕明剂量为每日25至75毫克，在初始治疗的48小时内完全停止了所有猝倒症、睡眠瘫痪症和入睡幻觉症的发作。这些患者在10至21个月的时间里一直没有症状。副作用包括男性患者出现阳痿，但未观察到血液学、心血管、肝脏或肾脏毒性作用。现有证据表明，这类药物会抑制那些控制快速眼动睡眠毒性成分的脑干系统。
